Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery

Am J Hematol. 2011 Apr;86(4):351-2. doi: 10.1002/ajh.21991.

Abstract

There are currently no recommendations indicating when stimulation should begin after autologous peripheral blood stem cell transplantation (PBSCT). We compared the outcome following between two treatment groups, in which daily granulocyte colony stimulating factor (G-CSF) administration began on either the fifth or the eighth day after PBSCT in lymphoma and myeloma patients. We studied eight clinical parameters: number of G-CSF injections, number of days of hospitalization, of red blood cell or platelet transfusions; days when body temperature exceeds 38°C; days of parenteral nutrition; weight loss and hospitalization costs. We studied also four biological parameters: number of CD34+ cells, days with leucocytes less than 1 × 10(9) /L, days with hemoglobin less than 90 g/L or with less than 50 × 10(9) /L of platelets. There were no statistical significant differences between the study arms. It seems that delayed stimulation by G-CSF after PBSCT is safety and does not seem to modify bone marrow recovery timing.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Bone Marrow / drug effects*
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hematopoietic Stem Cell Mobilization / methods
  • Humans
  • Lymphoma / drug therapy
  • Lymphoma / therapy*
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / therapy*
  • Peripheral Blood Stem Cell Transplantation*
  • Recombinant Proteins
  • Time Factors
  • Transplantation Conditioning
  • Treatment Outcome

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor